Thanks to all excellent responses. MSB early starter, multiple phase 3 trials, cash at bank, huge patent bank, good pharma partner, all adds up. SP problem in my view is result of no significant quantity buyer in the market - manipulator is a scavenger tiddler I believe mopping up retail sellers. Future funding calls would bring sophisticated investors (funds, pharma partners etc)to centre stage which makes current sp almost irrelevant. FDA approvals are everything and the money men can form a queue.
msb in fin rev re pushing fda , page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.070(6.57%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $3.980M | 3.944M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 56239 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 103125 | 2 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |